» Articles » PMID: 24874736

Serum-dependent Processing of Late Apoptotic Cells for Enhanced Efferocytosis

Overview
Journal Cell Death Dis
Date 2014 May 31
PMID 24874736
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Binding of the serum protein complement component C1q to the surface of dying cells facilitates their clearance by phagocytes in a process termed efferocytosis. Here, we investigate during which phase of apoptotic cell death progression C1q binding takes place. Purified C1q was found to bind to all dying cells and, albeit weaker, also to viable cells. The presence of serum abrogated completely the binding to viable cells. In addition, C1q binding to dying cells was limited to a specific subpopulation of late apoptotic/secondary necrotic cells. Co-culturing serum-treated apoptotic cells with human monocytes revealed a much higher phagocytosis of C1q-positive than of C1q-negative late apoptotic/secondary necrotic cells. But this phagocytosis-promoting activity could not be observed with purified C1q. Serum-treated C1q-positive late apoptotic/secondary necrotic cells exhibited a similar volume, a similar degraded protein composition, but a much lower DNA content in comparison with the remaining late apoptotic/secondary necrotic cells. This was mediated by a serum-bound nuclease activity that could be abrogated by G-actin, which is a specific inhibitor of serum DNase I. These results show that serum factors are involved in the prevention of C1q binding to viable cells and in the processing of late apoptotic/secondary necrotic cells promoting cell death progression toward apoptotic bodies. This process leads to the exposure of C1q-binding structures and facilitates efferocytosis.

Citing Articles

epHero - a tandem-fluorescent probe to track the fate of apoptotic cells during efferocytosis.

Singh S, Bensalem J, Hein L, Casey A, Makinen V, Sargeant T Cell Death Discov. 2024; 10(1):179.

PMID: 38632247 PMC: 11024195. DOI: 10.1038/s41420-024-01952-1.


Conserved and Distinct Elements of Phagocytosis in Human and .

Lukacsi S, Farkas Z, Saskoi E, Bajtay Z, Takacs-Vellai K Int J Mol Sci. 2021; 22(16).

PMID: 34445642 PMC: 8396242. DOI: 10.3390/ijms22168934.


Scorpion Venom Peptide Effects on Inhibiting Proliferation and Inducing Apoptosis in Canine Mammary Gland Tumor Cell Lines.

Panja K, Buranapraditkun S, Roytrakul S, Kovitvadhi A, Lertwatcharasarakul P, Nakagawa T Animals (Basel). 2021; 11(7).

PMID: 34359246 PMC: 8300387. DOI: 10.3390/ani11072119.


Phagocytic clearance of apoptotic, necrotic, necroptotic and pyroptotic cells.

Atkin-Smith G Biochem Soc Trans. 2021; 49(2):793-804.

PMID: 33843978 PMC: 8106503. DOI: 10.1042/BST20200696.


Phagocytosis of Necrotic Debris at Sites of Injury and Inflammation.

Westman J, Grinstein S, Marques P Front Immunol. 2020; 10:3030.

PMID: 31998312 PMC: 6962235. DOI: 10.3389/fimmu.2019.03030.


References
1.
Ortega-Gomez A, Perretti M, Soehnlein O . Resolution of inflammation: an integrated view. EMBO Mol Med. 2013; 5(5):661-74. PMC: 3662311. DOI: 10.1002/emmm.201202382. View

2.
Krajcovic M, Overholtzer M . Mechanisms of ploidy increase in human cancers: a new role for cell cannibalism. Cancer Res. 2012; 72(7):1596-601. PMC: 3319989. DOI: 10.1158/0008-5472.CAN-11-3127. View

3.
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C . Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. Br J Cancer. 2010; 103(8):1201-8. PMC: 2967072. DOI: 10.1038/sj.bjc.6605909. View

4.
Gullstrand B, Martensson U, Sturfelt G, Bengtsson A, Truedsson L . Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol. 2009; 156(2):303-11. PMC: 2759479. DOI: 10.1111/j.1365-2249.2009.03896.x. View

5.
Elliott M, Ravichandran K . Clearance of apoptotic cells: implications in health and disease. J Cell Biol. 2010; 189(7):1059-70. PMC: 2894449. DOI: 10.1083/jcb.201004096. View